Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for the month of October 2023 and dated October 10, 2023. The filing identifies I-MAB’s principal executive offices in Shanghai, China and indicates that the company files annual reports on Form 20-F.
The request metadata identifies the company as Novabridge Biosciences, but the filing itself identifies the registrant as I-MAB. The filing contains an index referencing Exhibit 99.1, a press release, but the press release text is not included in the provided filing content.
Financial and Operating Metrics
The provided filing text does not include revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes
The filing text does not provide information on changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not include management guidance, outlook, risk disclosures, contingencies, or unusual items. Any such information may be contained in Exhibit 99.1, which is referenced but not provided.
Investor Verification Items
- Confirm the correct registrant, because the filing identifies I-MAB rather than Novabridge Biosciences.
- Obtain and review Exhibit 99.1, the referenced press release.
- Verify whether the press release contains financial results, material corporate developments, guidance, or risk information.
- Confirm the filing date, reporting period, and applicable Form 20-F reporting status.